Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. Phase 1: Patients with either histologically or cytologically confirmed advanced or recurrent solid tumor, who failed standard therapy or for whom no effective standard therapy is available.~   Phase 2a: Patients with platinum-resistant/refractory ovarian, fallopian tube or primary peritoneal cancer (high-grade serous, endometrioid, or carcinosarcoma histotypes) or glioblastoma in first relapse.~3. Patients with solid tumors must have measurable disease according to Response Evaluation Criteria in Solid Tumors \[RECIST\] v1.1.~   Patients with recurrent glioblastoma must have measurable disease defined by contrast-enhancing magnetic resonance imaging.~4. Life expectancy ≥ 12 weeks~5. Acceptable organ and marrow function at baseline (protocol defined laboratory parameters)~6. Patients with solid tumors must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 and patients with recurrent glioblastoma must have an ECOG performance status ≤ 2.~7. Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~1. Patients with solid tumors who have received chemotherapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks prior to starting study drug or who have not recovered from side effects of prior therapies.~   Patients with recurrent glioblastoma who have: received radiotherapy within 12 weeks, unless there is a new area of enhancement consistent with recurrent tumor outside the radiation field, or there is histological confirmation of unequivocal tumor progression; received administration of prior antitumor chemotherapy within 4 weeks, or within 6 weeks for nitrosoureas; undergone surgical resection within 4 weeks or a stereotactic biopsy/core biopsy within 1 week prior to starting study drug, or have been treated previously with bevacizumab.~2. Patients who have had prior exposure to BAL101553.~3. Peripheral neuropathy ≥ CTCAE grade 2.~4. Uncontrolled intercurrent illness that would unduly increase the risk of toxicity or limit compliance with study requirements~5. Systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg at the screening visit.~6. Blood pressure (BP) combination treatment with more than two antihypertensive medications.~7. Women who are pregnant or breast-feeding. Men or women of reproductive potential who are not willing to apply effective birth control.~8. Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1 (Type: EXPERIMENTAL): Fixed 3+3 dose escalation of BAL101553 in patients with advanced solid tumors
- Phase 2a (Type: EXPERIMENTAL): BAL101553 at MTD in patients with platinum-resistant/refractory ovarian cancer or recurrent glioblastoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete